CD80 and neoplasm: The combination regime had a remarkable therapeutic efficacy of pre-existing lung metastases when compared to the use of either treatment alone, indicating that the suppression of T-regs with the anti-CD25 when combined with the immunotherapy pGmCSF-B7.1 allowed for an enhanced anti-tumor CD8 immune response with the decrease in the levels of metastatic nodules.